COMPARE · Data as of August 25, 2026
ADUS vs PACS
Verdict: Side-by-side breakdown using the Bull Rankings model. ADUS scored 74.8, PACS scored 70.6 — ADUS leads.
Compare another set
ADUS
Addus HomeCare Corporation
74.8
$121.09 · $2.3B
fundamentals as of
Score gap
4.2
ADUS leads
PACS
PACS Group, Inc.
70.6
$43.94 · $7.0B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestADUS21.2x
- Fastest growthADUS+15.9%
- Strongest balance sheetADUS0.09
- Highest qualityPACS63 / 100
- Largest discount to fair valueADUS-18%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ADUS
stronger →← stronger
PACS
59
Qualityreturns · margins · balance sheet
63
90
Growthrevenue & earnings expansion
90
79
Valuevaluation vs sector peers
62
ADUS and PACS split the three pillars evenly.
Fundamentals, head-to-head
ADUS
PACS
$155mC
FCF
$121mC
+15.9%B+
Rev
+15.2%B+
0.09B+
D/E
3.05D
21.2xB+
P/E
25.7xB
1.10B+
PEG
1.19B+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADUS
PACS
18% below
Price vs fair valuelower is cheaper
250% above
~0%/yr
Growth the price implies10-yr FCF · lower = less priced in
~38%/yr
+17%
1-yr DCF upside
-73%
+23%
5-yr DCF upside
-71%
+32%
10-yr DCF upside
-69%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ADUS
No notable signals flagged.
PACS
Why this score
- Short track record
The companies
ADUSAddus HomeCare Corporation
Why now
Medical Care Facilities · market cap $2.3b. Trading near 52-week high of $124.44 — momentum setup, limited technical margin of safety. Revenue growing +16%, comfortably above the S&P median. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $134.69 (implying +11% upside).
Moat
FCF converts 147% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction.
PACSPACS Group, Inc.
Why now
Medical Care Facilities · market cap $7.0b. 11% off the 52-week high of $49.49. Revenue growing +15%, comfortably above the S&P median. 5 sell-side analysts publish a mean 1-yr target of $59.20 (implying +35% upside).
Moat
ROE 24% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
D/E 3.05 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Net margin 4.9% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
ADUS leads PACS by 4.2 points (74.8 to 70.6), its sharpest advantage coming in D/E (grade B+).
Our AI analyst is busy right now, so this verdict is drawn directly from the pillars, grades and DCF above.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ADUS and PACS diverge
On the headline score the gap is 4.2 points in favor of ADUS. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueADUS 79.3 · PACS 62.4ADUS +16.9
- QualityADUS 59.0 · PACS 62.8PACS +3.8
- GrowthADUS 89.5 · PACS 89.7level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.